In the aftermath of the recent Minneapolis school shooting that left two children dead and 18 others injured, Health and Human Services Secretary Robert F. Kennedy Jr. suggested antidepressants may be partly to blame. Speaking on Fox & Friends, Kennedy linked selective serotonin reuptake inhibitors (SSRIs) a common class of antidepressants to the shooter’s violence, even though authorities have not confirmed whether the assailant was taking any psychiatric medications.

Kennedy announced that the National Institutes of Health (NIH) is launching new studies on psychiatric drugs and their potential connection to violent behavior. He emphasized so-called “black box warnings” that accompany certain medications, which note risks of suicidal thoughts, though not homicidal ideation.

His comments immediately sparked backlash among mental health experts, who argue that such claims are misleading, stigmatizing, and unsupported by evidence.

SSRIs—short for selective serotonin reuptake inhibitors—are among the most widely prescribed antidepressants in the world. They include familiar names such as fluoxetine (Prozac), sertraline (Zoloft), and citalopram (Celexa). More than 1 in 10 Americans take them, most often for depression, anxiety, or related mood disorders.

The drugs work by increasing serotonin, a neurotransmitter that plays a role in mood regulation, emotional processing, and impulse control. By preventing serotonin from being reabsorbed too quickly, SSRIs maintain higher levels of the chemical in the brain, which can improve symptoms of depression and anxiety for many patients.

Like any medication, SSRIs come with side effects—such as nausea, sexual dysfunction, and insomnia—but they are generally considered safe and effective when prescribed appropriately.

Do SSRIs Increase the Risk of Violence?

The scientific debate around SSRIs and violence has persisted since Prozac first entered the U.S. market in 1988. Critics point to anecdotal reports of individuals committing violent acts while taking antidepressants. Advocates highlight the life-saving benefits for millions of people struggling with mental illness.

A 2015 study in PLOS Medicine added fuel to the controversy. Researchers from Karolinska Institutet and Oxford University analyzed data from 850,000 Swedes prescribed SSRIs between 2006 and 2009. They found that adolescents and young adults (ages 15–24) had a slightly higher risk of violent crime convictions while on SSRIs compared to when they were not taking the drugs. However, the same pattern was not seen in older adults.

Crucially, the authors emphasized that the findings did not prove causation. Other factors—such as the severity of underlying mental illness, substance use, or socioeconomic stress—could explain the association.

What is The Complex Relationship Between Serotonin and Aggression?

At the neurobiological level, serotonin is thought to regulate aggression, impulse control, and emotional expression. Preclinical studies in animals suggest serotonin dysfunction may increase aggression, while boosting serotonin activity can reduce violent behaviors.

Yet, human studies have painted a more complicated picture. Some evidence suggests SSRIs reduce aggression by stabilizing mood and improving impulse control. Others have linked the drugs to irritability or agitation in a small subset of patients, particularly young people in the early weeks of treatment.

Experts note that aggression, irritability, and “anger attacks” are not the same as premeditated violence or mass shootings. Most people taking SSRIs experience symptom relief not violent behavior.

The Risk of Oversimplification

Mental health professionals caution against attributing mass shootings to antidepressants without evidence. The vast majority of SSRI users do not become violent. In fact, untreated depression and other mood disorders are more strongly associated with suicide and, in rare cases, violence, than the medications designed to treat them.

“Blaming SSRIs risks pushing people away from effective treatment,” psychiatrists argue. “The bigger issue in the U.S. is access to mental health care, combined with easy access to firearms—not antidepressants.”

It’s also important to note that countries where SSRIs are prescribed widely, such as Sweden, Japan, and the United Kingdom, do not experience mass shootings on the scale seen in the United States.

Politics, Stigma, and the Public Narrative

Kennedy’s comments fall into a larger cultural debate over psychiatric drugs, medical freedom, and the root causes of mass violence. Linking SSRIs to school shootings can resonate with a public that is often skeptical of pharmaceutical companies and searching for simple explanations for horrific events.

But experts warn that such claims risk stigmatizing people with mental illness, many of whom rely on antidepressants to function in daily life. Stigma may discourage people from seeking help, leading to more untreated mental health conditions—the very scenario that can increase risks of self-harm or harm to others.

The Minneapolis Shooting

In the case of the Minneapolis assailant, identified as Robin Westman, there is no evidence yet that SSRIs played any role. Court documents show a history of depression and troubling behavior, including admiration for mass murderers. Westman turned the gun on himself after the attack.

Mental health struggles, social isolation, extremist ideologies, and access to firearms appear to be more relevant factors in this tragedy than unproven medication links.

While there is ongoing research into SSRIs and their rare side effects, the consensus in psychiatry is clear: SSRIs are not a driving factor in mass shootings. The risk of violence remains extremely low, and the benefits of treating depression and anxiety far outweigh potential harms for most patients.

Future studies may shed more light on vulnerable subgroups—such as adolescents beginning treatment—but these questions require careful, evidence-based investigation, not speculation in the wake of tragedy.

The Minneapolis shooting has reignited debates over antidepressants, violence, and public safety. While RFK Jr.’s claims highlight public concern, the science does not support blaming SSRIs for mass shootings.

Disclaimer: This article is intended for informational purposes only and does not substitute professional medical advice, diagnosis, or treatment. The connection between antidepressants and violent behavior remains a subject of ongoing research, and no definitive conclusions should be drawn from individual cases. Always consult a licensed healthcare professional before starting, changing, or discontinuing any medication.

If you are struggling with your mental health: Please reach out to a qualified professional. In the U.S., you can dial 988 for the Suicide & Crisis Lifeline to get immediate support. You are not alone.

Several viral social media trends promoting physical appearance and self-improvement have raised health concerns, with some encouraging potentially dangerous practices.

One such trend, known as "heightmaxxing", has prompted warnings from doctors after reports emerged of teenage boys taking black-market cancer drugs in an attempt to grow taller.

Aolescents are reportedly experimenting with erdafitinib, often referred to online as "ERDA" or "Erta", a prescription drug approved to treat advanced bladder cancer. The trend appears to have gained traction following online discussions suggesting the medication could increase height.

"It's extremely concerning that teenagers are experimenting with powerful cancer medications in an attempt to grow taller," Dr. Stephanie Widmer, a New York City-based emergency medicine physician, told Fox News.

"These drugs were developed to treat serious medical conditions, not to enhance physical appearance, and taking them without a legitimate medical indication or physician supervision can have devastating consequences," Widmer added.

In a statement to magazine Rolling Stone, drugmaker Johnson & Johnson emphasised that erdafitinib has never been approved to stimulate height growth and that its safety and effectiveness have not been established in children or adolescents.

Can Erdafitinib Actually Increase Height?

Also read: After Ferritin Face, Doctors Warn About 'Ferritin Hair': What Are The Signs?

Medical research has documented unexpected growth spurts in children receiving erdafitinib for brain tumours. A 2024 study published in Hormone Research in Paediatrics described accelerated growth in two paediatric patients.

A separate case report documented a teenager who grew more than five inches during treatment but also developed serious skeletal complications.

However, doctors caution that these unexpected growth spurts do not necessarily indicate healthy skeletal development.

Dr. Jessica Gray, a family physician in Lubbock, Texas, warned that rapid, drug-induced growth could trigger dangerous structural problems, including premature growth plate damage and bone fractures, Fox News reported.

What Are The Health Risks Of Heightmaxxing With Cancer Drugs?

Read More: Joe Biden Opens Up About Life With Stage 4 Prostate Cancer: ‘It Hasn't Stopped Me, But Sometimes Slowed Down’

Widmer noted that height is largely determined by genetics and that there are no shortcuts to increasing it. Once the growth plates close towards the end of puberty, medications cannot reopen them. This means older adolescents taking erdafitinib could face serious health risks without any prospect of gaining height, she said.

"One of the biggest concerns is that these medications can cause serious side effects, including potentially permanent vision damage, elevated phosphate levels and other metabolic abnormalities," Widmer said.

"We're talking about adolescents whose bodies are still developing, and exposing them to these risks for a cosmetic goal is particularly troubling."

Erdafitinib works by blocking specific cellular signalling pathways involved in cancer cell growth. These pathways also play a role in bone development, which may help explain the unexpected growth observed in some paediatric patients.

Other reported side effects include skeletal pain, particularly in the hips or knees, mouth sores, loose nails and skin disorders.

What Should Parents Do?

Doctors advise parents to watch for unusual joint pain or unexplained physical changes and speak openly with their children if they suspect they are using medications obtained online.

Teenagers concerned about their height or growth should consult a paediatrician rather than experiment with prescription drugs.

"We should be encouraging teenagers to prioritize their health, not teaching them to gamble with it," Widmer said. "No amount of additional height is worth risking permanent damage to your vision or other serious and potentially unknown medical complications."

Global tuberculosis (TB) deaths have fallen by 35% since 2015, but progress in reducing new infections remains slow, according to a new report by the World Health Organization (WHO).

The Global Tuberculosis Report 2026 showed that TB remained the world's leading cause of death from a single infectious agent in 2025 and ranked 13th among all causes of death.

Based primarily on data reported to WHO by 187 countries and areas, the report estimates that 1.13 million people died from TB in 2025, while 10.6 million developed the disease.

TB Death Reduction Milestone Achieved Five Years Late

Compared with 1.74 million deaths in 2015, TB deaths fell by 35% in 2025, marking the achievement of the first milestone of the WHO End TB Strategy, originally set for 2020. However, the strategy's target of a 90% reduction in TB deaths by 2030 remains distant.

Progress in reducing new infections has been slower. The global TB incidence rate fell by just 14% between 2015 and 2025, against a target of a 50% reduction by 2025.

Also read: TB Treatment in 4 Months With 3 or Fewer Injections? WHO Pushes for Long-Acting Options

India Accounts For One In Four Global TB Cases

India was among two high-burden countries, alongside China, to achieve a 35% reduction in TB deaths since 2015. However, it continued to account for approximately one in four TB cases worldwide in 2025.

The report highlights persistent gaps in diagnosis, treatment, prevention and financing, underscoring the need for sustained investment and stronger health services.

International donor funding for TB prevention, diagnosis and treatment in low- and middle-income countries fell by 14% in 2025, from US$1.1 billion to US$940 million.

WHO cautions that estimates of TB disease burden should be interpreted using the latest published time series, as direct comparisons with estimates from previous report editions are not appropriate.

"The continued decline in TB cases and deaths is very encouraging, especially given the challenges many countries have faced from funding cuts. And yet, more than one million people still die each year from a disease that is preventable and treatable," WHO Director-General Tedros Adhanom Ghebreyesus said.

He urged countries and partners to expand access to TB services, protect essential funding and accelerate the development of new tools to end the epidemic.

Which Countries Account For The Most TB Cases?

The 30 high TB burden countries accounted for 88% of global cases in 2025. The eight countries with the largest shares were:

• India: Approximately 25%
• Indonesia: 10%
• Philippines: 6.8%
• China: 6.5%
• Pakistan: 6.4%
• Nigeria: 4.9%
• Democratic Republic of the Congo: 3.9%
• Bangladesh: 3.7%

Of all people who developed TB in 2025, 54% were men, 35% were women and 11% were children.

Key Findings: TB Diagnosis And Drug-Resistant Treatment

Read More: 94% Of TB Patients Report Anxiety, 77% Depression: Study Highlights Mental Health Toll Of India's TB Burden

The report also highlights gaps in TB diagnosis and treatment, particularly for drug-resistant forms of the disease.

An estimated 10.6 million people developed TB in 2025, but only 8.4 million were diagnosed and reported to WHO. The remaining estimated cases were not captured by diagnosis and reporting systems.

Other findings include:

• Rapid testing: 59% of newly diagnosed patients were initially tested using a rapid diagnostic test, up from 54% in 2024. This remains below the 2027 target of 100%.
• Drug-resistant TB: 155,333 people received treatment for rifampicin-resistant TB (RR-TB), accounting for 42% of the estimated 370,000 people who developed the disease.
• Shorter treatment: Six-month treatment regimens were used for 42% of people treated for RR-TB, compared with 18% in 2024.
• Treatment success: Success rates remained around 90% for drug-susceptible TB and 70% for RR-TB.

TB Risk Factors And Vaccine Development

The report identifies several factors associated with the number of people developing TB each year at the country level. These include income per capita and the prevalence of undernutrition, diabetes, alcohol use disorders, smoking and HIV infection.

TB vaccine research is also progressing. As of August 2026, 12 TB vaccines were in active clinical development, including three in Phase 3 trials.

TB Prevention And Treatment Coverage

In 2025, 5.2 million people at high risk of developing TB received preventive treatment, including 3.7 million household contacts of people diagnosed with TB and 1.5 million people living with HIV.

Coverage remained uneven:

• Among people living with HIV, preventive treatment coverage increased from 58% in 2024 to 60% in 2025.
• Among household contacts of people diagnosed with TB, coverage rose from 25% to 26%.

Between 2000 and 2025, TB treatment is estimated to have prevented 86 million deaths.

TB Funding Falls Short Of Global Targets

Funding for TB prevention, diagnosis and treatment in low- and middle-income countries reached US$6.6 billion in 2025, up from US$6 billion in 2024. However, this remains substantially below the annual target of US$22 billion by 2027.

• Domestic funding: Increased from US$4.9 billion in 2024 to US$5.63 billion in 2025.
• International donor funding: Declined by 14%, from US$1.1 billion to US$940 million.

The economic burden also remains significant. About 50% of people with TB and their households face costs exceeding 20% of their annual household income, highlighting the need for stronger universal health coverage and social protection.

The SARS-CoV-2 virus is back with a new variant. The deadly virus behind COVID-19 pandemic continues to evolve, and a new COVID-19 variant, PJ.2.1, has been detected in several countries. Its spread and spike protein mutations have raised questions about its potential to transmit, symptoms and severity.

However, doctors said there is currently no evidence that the variant causes more severe illness or significantly different symptoms. They stressed the need to strengthen genomic surveillance in India to track its possible circulation in the country.

PJ.2.1: Countries Reporting Cases

According to an October preprint study that has not yet undergone peer review, the first confirmed PJ.2.1 sample was detected on May 2, 2026, in Ontario, Canada.

The variant was subsequently identified in other parts of Canada and in New York on June 30. Cases were later reported in several US states.

It has also been reported in Spain, France, Israel, Singapore, Australia and New Zealand.

PJ.2.1: Is India At Risk?

Also read: New COVID-19 Variant PJ.2.1 Spreads Globally: WHO Says Symptoms Resemble Cold, Flu

PJ.2.1 is a heavily mutated descendant of the Omicron family of SARS-CoV-2. It carries multiple mutations in its spike protein, which helps the virus enter human cells.

Dr Jatin Ahuja, Consultant, Infectious Disease, Indraprastha Apollo Hospital, Delhi, said the emergence of a new variant does not automatically indicate a change in India's overall COVID-19 situation.

"Continued genomic surveillance will help establish whether PJ.2.1 is circulating in the country. Authorities should also monitor infection patterns and any changes in hospitalisations," he told HealthandMe.

However, he stressed that "at present, there is no reason for undue concern. The focus should remain on monitoring developments and following routine precautions against respiratory infections".

What Do PJ.2.1's Mutations Mean?

Dr Ahuja said it is important to look beyond a variant's name or mutations and assess whether these changes affect how the virus spreads, evades existing immunity and causes illness.

"PJ.2.1 is worth monitoring because of changes in its spike protein, which plays a role in the virus entering human cells. These changes have raised questions about its ability to interact with human cells and potentially gain a transmission advantage," he said.

However, changes in the virus's behaviour at the cellular level do not necessarily translate into more severe illness in patients.

Read More: XFG COVID Variant: What India Should Watch As Cases Rise In UK And France

PJ.2.1: Are There New Symptoms?

Dr Tushar Tayal, Associate Director – Internal Medicine, CK Birla Hospital, Gurugram, said there is currently insufficient clinical evidence to suggest that the variant causes more severe illness or produces distinctly different symptoms.

"People should watch for fever, cough, sore throat, fatigue and gastrointestinal symptoms, and consider testing if they develop signs of infection," he told HealthandMe.

Dr Ahuja also said there is no established evidence that PJ.2.1 causes more severe COVID-19, increases the likelihood of hospitalisation or produces symptoms significantly different from those associated with earlier variants.

The World Health Organization (WHO) said symptoms associated with the variant may resemble those of the common cold or flu.

"Symptoms of COVID-19, influenza and other respiratory infections can coincide. Thus, based on symptoms alone, it is impossible to determine with certainty which respiratory virus caused the infection," the WHO was quoted as saying by RIA Novosti.

The global health body said diagnostic testing may be important when identifying the virus could influence treatment decisions.

According to the WHO, possible COVID-19 symptoms include:

• High fever
• Cough
• Sore throat
• Blocked or runny nose
• Headache
• Muscle aches
• Severe fatigue

Some people may also experience digestive problems, shortness of breath or changes in their sense of smell and taste. These symptoms are not unique to COVID-19, as seasonal influenza and other respiratory infections can cause similar symptoms.

The WHO emphasised that symptoms alone cannot reliably identify the virus responsible for an infection. Laboratory testing may be necessary when knowing the cause could affect treatment decisions.

PJ.2.1: How Can You Prevent Your Risk?

Dr Tayal recommended taking routine precautions, including wearing a well-fitted N95 mask in crowded or poorly ventilated spaces, improving indoor ventilation and maintaining hand hygiene.

Older adults and people with underlying health conditions should seek medical advice promptly if they develop respiratory symptoms.

People should continue to take respiratory infections seriously. However, the emergence of PJ.2.1 should not be interpreted as an indication of another major COVID-19 outbreak. The experts noted that surveillance and clinical evidence, rather than speculation, should guide the response.